title: [Latin America: clinical responses to the antipsychotic drugs].
abstract: OBJECTIVE
  To compare the effectiveness of a 12 months antipsychotic monotherapy treatment with Olanzapine, risperidone and an atypical antipsychotic drug in Latin American patients with schizophrenia.
  
  
  METHODS
  The outcomes of effectiveness and tolerability were evaluated in outpatients with schizophrenia belonging to a large sample (N=7658) in a prospective, international trial carried out in 27 countries. The results for the population of Latin America were presented.
  
  
  RESULTS
  The probabilities of response were higher for Olanzapine than Risperidone and the atypical antipsychotic drugs. (p < or = 0.05) and for risperidone compared with the atypical antipsychotic drugs. (p < or = 0.05). Olanzapine was better tolerated as regarding the extrapiramidals symptoms and the sexual disfunction, although it was associated to a higher weight gain, as compared to the other groups of the trial.
  
  
  CONCLUSIONS
  the trial indicated that in the Latin American patients with schizophrenia, it is likely that Olanzapine induces clinical responses and has lower incidences on side effects, when compared with risperidone or atypical antipsychotic drugs.
authors.affiliation: Médica de Investigación Clinica, Eli Lilly and Company, San Pablo, SP, Brasil. sheilat72@comcast.net
authors.forename: Sheila
authors.initials: S
authors.lastname: Assunção
authors.forename: José
authors.initials: J
authors.lastname: Jiménez
authors.forename: Nora
authors.initials: N
authors.lastname: Pacheco
authors.forename: Fabiola
authors.initials: F
authors.lastname: Navarro Marún
authors.forename: Douglas
authors.initials: D
authors.lastname: Quintero
authors.forename: Isabel
authors.initials: I
authors.lastname: Aspilcueta Flores
authors.forename: Carlos L
authors.initials: CL
authors.lastname: Pérez Desanti
authors.forename: Arsenio
authors.initials: A
authors.lastname: Rosado-Franco
authors.forename: Guillermo
authors.initials: G
authors.lastname: Tapia Paniagua
authors.forename: Amado
authors.initials: A
authors.lastname: Nieto Caraveo
authors.forename: Sergio
authors.initials: S
authors.lastname: Sanchez Cázares
authors.forename: Jaime
authors.initials: J
authors.lastname: Aguilar Gasca
authors.forename: Erick
authors.initials: E
authors.lastname: Landa Fournais
authors.forename: Joanna
authors.initials: J
authors.lastname: Leadbetter
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007843:Latin America; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008605:Mental Health Services / Q000458:organization & administration*; D000077152:Olanzapine; D018967:Risperidone / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine